Enlivex focuses resources on Allocetra Phase 2b knee osteoarthritis trial

• Enlivex announced immediate cost cuts to focus resources on its Phase 2b Allocetra trial for moderate-to-severe age-related primary knee osteoarthritis.
• The plan winds down non-trial research and development, reducing the workforce by approximately 60% to substantially lower cash burn.
• Management salaries will fall 20%; the CEO's salary will decline 40%.
• The trial evaluates patients aged 64 and older, with six-month topline results expected by mid-2027.
• Completed Phase 1/2a results showed meaningful improvements in knee pain and function versus placebo at three and six months, with favorable safety.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190817PRIMZONEFULLFEED9848381) on October 19, 2026, and is solely responsible for the information contained therein.